ICCC Insider Trading

Insider Ownership Percentage: 6.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

ImmuCell Insider Trading History Chart

This chart shows the insider buying and selling history at ImmuCell by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5k$0$5kTotal Insider BuyingTotal Insider Selling

ImmuCell Share Price & Price History

Current Price: $4.81
Price Change: Price Decrease of -0.57 (-10.59%)
As of 04/8/2025 05:00 PM ET

This chart shows the closing price history over time for ICCC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$4.81Closing price on 04/08/25:

ImmuCell Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for ImmuCell (NASDAQ:ICCC)

13.47% of ImmuCell stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ICCC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$939kbought$726ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500k$0$500kTotal InflowsTotal Outflows
ImmuCell logo
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Read More on ImmuCell

Today's Range

Now: $4.81
Low: $4.76
High: $5.38

50 Day Range

MA: $5.09
Low: $4.78
High: $5.48

52 Week Range

Now: $4.81
Low: $3.34
High: $5.82

Volume

35,125 shs

Average Volume

19,660 shs

Market Capitalization

$43.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39